Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 607 Shares of Humana Inc. (NYSE:HUM)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its position in shares of Humana Inc. (NYSE:HUM) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,603 shares of the insurance provider’s stock after selling 607 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Humana were worth $6,496,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of HUM. Quest Partners LLC bought a new stake in Humana during the 3rd quarter valued at approximately $701,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Humana in the 3rd quarter worth approximately $1,778,000. Moors & Cabot Inc. boosted its position in shares of Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares in the last quarter. Landscape Capital Management L.L.C. boosted its position in shares of Humana by 54.4% in the 3rd quarter. Landscape Capital Management L.L.C. now owns 2,451 shares of the insurance provider’s stock worth $776,000 after purchasing an additional 864 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Humana by 42.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider’s stock worth $124,053,000 after purchasing an additional 115,820 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.37% of the stock is owned by insiders.

Humana Price Performance

NYSE HUM opened at $266.33 on Friday. The business’s fifty day moving average price is $271.33 and its 200-day moving average price is $276.92. The stock has a market capitalization of $32.14 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. Humana’s dividend payout ratio is currently 35.58%.

Wall Street Analyst Weigh In

HUM has been the topic of a number of analyst reports. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Barclays boosted their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Eighteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.